Bedaquiline backed by FDA panel
FDA Advisory Committee Recommends Accelerated Approval of JNJ’s Investigational Multi-Drug Resistant Tuberculosis Treatment Bedaquiline
This week while attending the Partnering for Cures meeting in New York (http://www.
Surprisingly, little mention of this panel decision was made at the meeting in New York, which is unfortunate because the background story behind it illustrates many of the aspects discussed at the meeting. For example Public Private Partnerships (J&J and TB Alliance), PDUFA, Philanthropy etc… Maybe next year it will be highlighted. While not likely to be a very profitable drug it will provide good visibility for J&J and help to bolster the image of a company and an industry that has taken a lot of setbacks in recent years.
Let’s hope it encourages other companies to collaborate to discover drugs for this disease that are faster acting and less toxic than current treatments and that it does not take another 40 years to get there.
Sean Ekins Ph.D, D.Sc.
VP, Science. CDD.